- Achieve Life Sciences (ACHV) is a $685 million biotech focused on cytisinicline-based nicotine addiction treatments, showing strong recent technical momentum.
- ACHV has surged 173% over 52 weeks.
- Shares recently hit a 3-year high earlier in July.
- Despite robust technicals, ACHV remains highly speculative, as it has not yet begun monetizing its research pipeline.